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Introduction: In this study, our aim was to elucidate the role of four polymorphisms identified in a prior large
genome-wide association study (GWAS) in which the investigators analyzed the responses of patients with
rheumatoid arthritis (RA) to treatment with tumor necrosis factor inhibitors (TNFi). The authors of that study
reported that the four genetic variants were significantly associated. However, none of the associations reached
GWAS significance, and two subsequent studies failed to replicate these associations.
Methods: The four polymorphisms (rs12081765, rs1532269, rs17301249 and rs7305646) were genotyped in a total
of 634 TNFi-treated RA patients of Spanish Caucasian origin. Four outcomes were evaluated: changes in the Disease
Activity Score in 28 joints (DAS28) after 6 and 12 months of treatment and classification according to the European
League Against Rheumatism (EULAR) response criteria at the same time points. Association with DAS28 changes
was assessed by linear regression using an additive genetic model. Contingency tables of genotype and allele
frequencies between EULAR responder and nonresponder patients were compared. In addition, we combined our
data with those of previously reported studies in a meta-analysis including 2,998 RA patients.
Results: None of the four genetic variants showed an association with response to TNFi in any of the four
outcomes analyzed in our Spanish patients. In addition, only rs1532269 yielded a suggestive association (P = 0.0033)
with the response to TNFi when available data from previous studies were combined in the meta-analysis.
Conclusion: Our data suggest that the rs12081765, rs1532269, rs17301249 and rs7305646 genetic variants do not
have a role as genetic predictors of TNFi treatment outcomes.* Correspondence: anamaort@ipb.csic.es
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Rheumatoid arthritis (RA) is a systemic autoimmune dis-
ease characterized by chronic inflammation of the synovial
joints resulting in joint destruction, polyarthritis and func-
tional disability. This inflammatory condition affects ap-
proximately 1% of the Caucasian population, making it a
significant cause of comorbidity and mortality [1].
In recent years, the use of tumor necrosis factor inhib-
itors (TNFi) has resulted in an improvement in the treat-
ment of RA patients by reducing both inflammation and
joint damage [2-4], and their clinical use has become
widespread. However, a percentage of patients do not re-
spond adequately to this therapy; therefore, the current
use of these agents is based on a trial-and-error ap-
proach [5,6]. Given the adverse effects and the high cost
of this type of therapy, the establishment of pharmaco-
genetic markers to predict the response to TNFi treat-
ment is a highly desirable goal.
Recently, researchers in pharmacogenetic studies have
reported several genetic variants associated with clinical
response to treatment with TNFi [7-11]. However, to
date, only the PTPRC and PDE3A-SLCO1C1 loci have
been associated in more than a single study [12-14].
In 2011, Plant et al. [8] performed a genome-wide as-
sociation study (GWAS) in a large number of RA pa-
tients from the United Kingdom treated with TNFi. These
investigators used a three-stage study design. The meta-
analysis combining stages 1, 2 and 3 cohorts yielded four
single-nucleotide polymorphisms (SNPs) putatively associ-
ated with the TNFi response at 6 months, although these
associations did not reach the GWAS significance level.
Two of the genetic variants mapped within genes,
PDZ domain-containing 2 (PDZD2) and eyes absent
homolog 4 (EYA4), and two polymorphisms mapped
to intergenic regions on chromosomes 1 and 12. How-
ever, two subsequent GWASs conducted in European
RA patients, whose treatment response was evaluated
at 14 weeks, failed to replicate association with any of
the four loci [9,10].
The aim of our study was to assess the role of the four
genetic variants identified by Plant et al. [8] with regard
to their association with response to TNFi using a large
number of RA Spanish patients, as well as to conduct a
meta-analysis including previous data.
Methods
Patients
Two sets of RA patients of Spanish ancestry treated with
TNFi (infliximab, adalimumab and etanercept) were in-
cluded in the study. Collection 1 comprised 438 patients,
and collection 2 included 196 patients. All patients were
classified according to the 1987 American Rheumatism
Association criteria [15]. Informed written consent from
all participants and approval from the local ethicalcommittees (Comité Ético de Investigación Clínica de
Galicia and Comité de Bioética del Consejo Superior de
Investigaciones Científicas) were obtained in accordance
with the tenets of the Declaration of Helsinki. The char-
acteristics of the patients enrolled in this study are
shown in Table 1.
Treatment outcomes
The Disease Activity Score in 28 joints (DAS28) was mea-
sured at baseline and at 6 and 12 months after the first
TNFi infusion. Two scales were considered to assess the
efficacy of the TNFi therapy. First, the absolute change in
DAS28 (ΔDAS28 = DAS28end – DAS28baseline) at 6 and 12
months of follow-up. Second, patients were classified as
responders (good and moderate) or nonresponders at 6
and 12 months according to the European League Against
Rheumatism (EULAR) response criteria [16].
Genotyping
Genomic DNA was extracted from peripheral white
blood cells or saliva using standard procedures. Four
SNPs—rs1532269 and rs17301249, intronic polymor-
phisms mapped within PDZD2 and EYA4, respectively,
and rs12081765 and rs7305646 located at intergenic
regions on chromosomes 1 and 12, respectively—were
genotyped using a single-base extension technology
(SNaPshot Multiplex Kit; Applied Biosystems, Foster
City, CA, USA) in a multiplex PCR experiment
(KAPA2G Fast HotStart; Kapa Biosystems, Wilmington,
MA, USA) in collection 1 and using TaqMan allelic dis-
crimination assays on a 7900HT Fast Real-Time PCR
System, both purchased from Applied Biosystems, in col-
lection 2. A deviation from Hardy–Weinberg equilibrium
(HWE) was detected for the rs1532269 polymorphism in
collection 2, so that SNP was genotyped in this sample set
using the same methodology used for collection 1.
Statistical analysis
Power calculations were performed using Quanto version
1.2.4 software [17]. All SNPs were tested for deviations
from HWE. The association between SNPs and responses
to TNFi was evaluated in two ways. In the first method,
linear regression analysis using ΔDAS28 as the continuous
dependent variable was performed under an additive gen-
etic model using Plink version 1.07 statistical software
[18]. A t-test was used to identify polymorphisms associ-
ated with the response. In the second method, genotype
and allele frequencies between EULAR-defined responder
and nonresponder patients were compared. Plink was
used to create 2 × 2 or 2 × 3 contingency tables and to
perform a χ2 test and/or Fisher’s exact test. Odds ratios
(ORs) and 95% confidence intervals (CIs) were calculated
according to Woolf ’s method. Because our present study
is a replication study, no correction was applied to the
Table 1 Baseline characteristics of the rheumatoid
arthritis patientsa
Baseline characteristics Collection 1(N = 438)
Collection 2
(N = 196)
Age, mean ± SD years 61.0 ± 12.04 56.3 ± 14.77
Age at diagnosis, mean ± SD years 44.95 ± 13.03 42.99 ± 13.69
Females, n (%) 365 (83.3) 160 (81.6)
Disease duration, mean ± SD years 16.45 ± 8.34 12.93 ± 8.47
Rheumatoid factor–positive, n (%) 340 (77.8) 141 (71.94)
Anti-CCP-positive, n (%) 250 (69.6)b 125 (73.1)c
Smoking status, n (%)
Ever-smoker 51 (16.0)b 20 (13.9)c
Never-smoker 267 (84.0)b 124 (86.1)c
Health status, mean ± SD
DAS28 at baseline 5.86 ± 1.12 5.36 ± 1.13
Treatment, n (%)
Concurrent DMARDs 252 (92.6)b 159 (81.1)
Previous biologic agents 0 (0) 14 (10.2)c
Anti-TNF drugs, n (%)
Infliximab 245 (55.9) 62 (31.6)
Etanercept 113 (25.8) 21 (10.7)
Adalimumab 80 (18.3) 113 (57.7)
EULAR-defined response at 6 months,
n (%)
Responders 337 (80.4) 167 (85.2)
Nonresponders 82 (19.6) 29 (14.8)
EULAR-defined response at 12 months,
n (%)
Responders 259 (82.5) 118 (88.1)
Nonresponders 55 (17.5) 16 (11.9)
aAnti-CCP, Anti–cyclic citrullinated peptide antibody; DAS28, Disease Activity
Score in 28 joints; DMARD, Disease-modifying antirheumatic drug; EULAR,
European League Against Rheumatism; TNF, Tumor necrosis factor. bData are
from <85% of the patients: 359 for anti-CCP status, 318 for smoking status and
272 for concurrent DMARD treatment. cData are from <70% of the patients:
171 for anti-CCP status, 144 for smoking status and 137 for previous biologic
agent treatment.
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6 months. In the analyses involving the TNFi efficacy at 12
months, however, P-values were corrected by using the
Benjamini–Hochberg step-up procedure to control for
false discovery rates (FDRs) in multiple testing [19]. The
results were considered statistically significant when P-
values were lower than 0.05.
Clinical variables previously identified as being inde-
pendent predictors of efficacy of TNFi, including age,
gender, smoking status, rheumatoid factor status, anti–
cyclic citrullinated peptide antibody (anti-CCP) status,
DAS28 at baseline, concurrent and previous treatment
and TNFi, were assessed for association with treatmentresponse in a multivariate regression analysis using STA-
TISTICA version 7.0 software (StatSoft, Tulsa, OK, USA)
and Plink software in collections 1 and 2, respectively.
Only baseline DAS28, gender and TNFi were associated
with the efficacy of the therapy. Accordingly, analyses
were adjusted for these three variables.
The analysis of the combined data from our study and
the previous reports [8-10] was performed using Plink.
Heterogeneity between studies was assessed using
Cochran’s Q and I2 statistics [20]. Pooled analyses were
performed by using the Mantel–Haenszel test under
the fixed-effects model or the DerSimonian–Laird test
under the random-effects model when heterogeneity
was detected. The results were considered to be statistically
significant when P-values were lower than 5 × 105.00E−08.
Results
All of the four studied polymorphisms conformed to
HWE expectations (P > 0.01). The genotyping success
rate was higher than 95%.
Replication study
First, we analyzed the association between the four tested
polymorphisms and the efficacy of the TNFi therapy in the
438 RA patients of Spanish Caucasian origin in collection
1. As shown in Table 2, in the linear regression analysis
using ΔDAS28, none of the analyzed genetic variants were
associated with the clinical response at 6 months (P =
0.570, P = 0.831, P = 0.181 and P = 0.244 for rs12081765,
rs1532269, rs17301249 and rs7305646, respectively) or at
12 months (P = 0.716, P = 0.647, P = 0.416 and P = 0.182
for rs12081765, rs1532269, rs17301249 and rs7305646, re-
spectively). Likewise, when allele frequencies were com-
pared between responder and nonresponder patients, no
association with the EULAR-defined response at 6 or 12
months was observed for any of the analyzed polymor-
phisms (see Additional file 1: Tables S1 and S2).
In the subsequent analysis in collection 2, none of the
tested polymorphisms showed an association with ΔDAS28
at 6 months (Table 2) (P = 0.995, P = 0.830, P = 0.458 and
P = 0.661 for rs12081765, rs1532269, rs17301249 and
rs7305646, respectively) or in the stratified analysis accord-
ing to the EULAR-defined response (see Additional file 1:
Table S1). When TNFi efficacy was evaluated at 12 months,
the rs1532269 polymorphism showed an association with
ΔDAS28 at that time point (Table 2) (P = 0.022, β = 0.335);
however, statistical significance was lost after correction
using the Benjamini–Hochberg step-up procedure for
FDR (PFDR = 0.087). No association of this SNP with the
EULAR-defined response at the 12-month time point was
observed (see Additional file 1: Table S2).
No heterogeneity was observed (P > 0.1 by Cochran’s Q-
statistic) before we performed the meta-analysis of the two
Spanish collections. No association between rs12081765,
Table 2 Association of the four single-nucleotide polymorphisms with changes in Disease Activity Score in 28 joints at
6 and 12 months in Spanish rheumatoid arthritis patientsa
6 months 12 months
Collection 1 (N = 419) Collection 2 (N = 193) Collection 1 (N = 314) Collection 2 (N = 134)
SNP Locus 1/2 MAF P-valueb βb MAF P-valueb βb MAF P-valueb βb MAF P-valueb βb
rs12081765 Intergenic A/G 0.415 0.570 0.055 0.458 0.995 0.001 0.411 0.716 0.043 0.408 0.677 0.062
rs1532269 PDZ2D C/G 0.375 0.831 0.020 0.418 0.830 0.022 0.400 0.647 0.051 0.420 0.022 0.335
rs17301249 EYA4 C/G 0.121 0.181 −0.190 0.132 0.458 0.120 0.131 0.416 −0.137 0.154 0.529 0.135
rs7305646 Intergenic T/C 0.474 0.244 −0.117 0.487 0.661 −0.049 0.486 0.182 −0.161 0.473 0.554 −0.093
a1, Minor allele, 2, Major allele; MAF, Minor allele frequency; SNP, Single-nucleotide polymorphism. bAdjusted for gender, anti–tumor necrosis factor treatment and
Disease Activity Score in 28 joints at baseline.
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the TNFi therapy was evident in this pooled analysis for
any of the outcomes considered as measured by ΔDAS28
(Table 3) and EULAR-defined response (see Additional
file 1: Table S3).Meta-analysis of all available studies
We combined our data with the results of three previous
studies in order to assess the global status of the four poly-
morphisms [8-10]. Results corresponding to ΔDAS28 at 14
weeks from two of the studies [9,10] were combined with
results at 24 weeks from the other two studies ([8] and
present meta-analysis). A total of 2,998 RA patients were
included in the meta-analysis, which had >90% power to
detect a difference of ≥0.6 units in ΔDAS28 at the GWAS
significance threshold (P ≤ 5.0E-08) for allele frequen-
cies ≥10%. Only one of the polymorphisms, rs1532269,
showed a suggestive association (fixed-effects model: P =
0.0033, β = 0.107) (Table 4), although it did not reach the
GWAS significance level. The other three were not associ-
ated with ΔDAS28 at 3 to 6 months (random-effects
model: P = 0.102, β = 0.068; P = 0.063, β = −0.138; and
P = 0.085, β = −0.095, for rs12081765, rs17301249 and
rs7305646, respectively) (Table 4). When data derived from
the four studies were pooled, heterogeneity for the
rs12081765, rs17301249 and rs7305646 variants was evi-
dent (Cochran’s Q-statistic P < 0.05, I2 > 40%).Table 3 Pooled analysis of the tested polymorphisms in the t
Single-nucleotide polymorphism Locus P
rs12081765 Intergenic 0
rs1532269 PDZ2D 0
rs17301249 EYA4 0
rs7305646 Intergenic 0Discussion
Our results make it unlikely that any of the four poly-
morphisms identified by Plant et al. could be used as
genetic predictors of TNFi treatment outcomes, because
they were not associated in our large Spanish RA study.
This lack of association represents a very relevant find-
ing because, to the best of our knowledge, our present
study is the first in which the association of these SNPs
was analyzed with the same treatment outcomes used
for their identification. In addition, the combined ana-
lysis with the three previous studies included in our
meta-analysis [8-10] showed only a suggestive associ-
ation of one of the four polymorphisms (even weaker
than that reported in the study by Plant et al. [8]). These
findings seem to exclude effects of sufficient magnitude
to be useful in predicting response to treatment.
The lack of replication in our study could be ascribed to
multiple differences between studies. It is commonly im-
possible to identify one of them as being more relevant
than the others. Genetic differences between populations
are an unlikely explanation of the results, given that the al-
lele frequencies of the four tested polymorphisms were
very similar between studies. Clinical differences between
the patients with RA included in the different reports are
possible and difficult to exclude. In this regard, it has
already been mentioned that Plant et al. [8] evaluated the
response to TNFi at 6 months, whereas the two sub-
sequent studies used the response at 14 weeks. However,wo Spanish cohorts
Meta-analysis
6 months 12 months
-value β P-value β
.677 0.029 0.586 0.050
.762 0.021 0.074 0.158
.607 −0.055 0.8041 −0.033
.246 −0.086 0.1549 −0.136
Table 4 Meta-analysis of association of four single-nucleotide polymorphisms with changes in Disease Activity Score in
28 joints in all available studiesa
rs12081765 rs1532269 rs17301249 rs7305646
Study MAF P-value β MAF P-value β MAF P-value β MAF P-value β
Plant et al. [8] Cohort 1 (n = 566) 0.43 7.52E-04 0.29 0.37 7.11E-04 0.3 0.20 3.37E-04 −0.38 0.47 9.16E-04 −0.28
Cohort 2 (n = 379) 0.46 0.062 0.19 0.35 0.079 0.19 0.19 0.045 −0.24 0.49 0.049 −0.21
Cohort 3 (n = 341) 0.47 0.712 0.04 0.34 0.701 0.04 0.19 0.261 −0.14 0.50 0.292 −0.11
Krintel et al. [9] Copenhagen cohort
(n = 196)
0.47 0.940 0.008 0.36 0.360 0.116 0.18 0.570 0.89 0.48 0.740 0.042
Umicevic Mirkov et al. [10] Dutch stage 1 cohort
(n = 882)
0.39 0.730 −0.024 0.43 0.920 0.051 0.18 0.360 −0.05 0.50 0.390 0.05
Present study Collection 1 (n = 438) 0.42 0.570 0.055 0.38 0.831 0.020 0.12 0.181 −0.190 0.47 0.244 −0.117
Collection 2 (n = 196) 0.46 0.995 0.001 0.42 0.830 0.022 0.13 0.458 0.120 0.49 0.661 −0.049
Meta-analysis N = 2,998 0.102 0.068 0.0033 0.107 0.063 −0.138 0.085 −0.095
aMAF, Minor allele frequency.
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ation at 6 months evidenced negative results. A common
cause of discrepant results is the overestimation of the
true effect in the discovery study. This phenomenon has
been characterized as the “winner’s curse,” and it has been
very prevalent in genetic association studies [21]. It should
be noted that the four SNPs studied by Plant et al. [8]
showed the highest effects in the discovery cohort (which
was the only one with a clear association between these
four polymorphisms and the clinical response), whereas
the three replication studies showed lower effect sizes (β-
values less different from zero), thus supporting this possi-
bility. Indeed, significant heterogeneity between studies
was observed in the meta-analysis of three of the four ana-
lyzed genetic variants. Interestingly, this heterogeneity dis-
appeared when the discovery cohort of Plant et al. was
removed [8]. Therefore, variables other than the presence
of the four SNPs considered herein could have influenced
the efficacy of TNFi in this cohort, accounting for its
singularity.
Other GWASs of responses to TNFi treatment in RA
have been published [7,9-11]. This approach represents
an important step forward in the understanding of the
influence of genetic variability on the efficacy of this
therapy. Only one of the observed associations has been
found to reach the GWAS statistical significance level,
however, and only after combination with data derived
from replication studies [12]. This highlights the import-
ant role of validation studies in determining the status of
the remaining GWAS findings. It is to be expected that
these combined efforts will produce useful insights.
Conclusions
The association of four polymorphisms (rs12081765,
rs1532269, rs17301249 and rs7305646) previously identi-
fied as being associated with TNFi treatment responsewas not confirmed in the present study. Our results in-
dicate that these four genetic variants are not useful pre-
dictors of response to TNFi in patients with RA.
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